Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Neoplasms 1Lymphoma 1Iron Overload 1Hemoglobinopathies 1Diabetes Mellitus, Type 2 1Diabetes Mellitus, Type 1 1Diabetes Mellitus 1Cushing Syndrome 1Colorectal Neoplasms 1Bone Metastases 1

Interventions

otelixizumab 1golimumab 1Waist-Hip Ratio 1Waist Circumference 1Time 1Sex Characteristics 1Islets of Langerhans Transplantation 1Insulin 1High-Intensity Interval Training 1Exenatide 1Etanercept 1Echocardiography 1Continuous Glucose Monitoring 1Cardiovascular Physiological Phenomena 1Body Mass Index 1Body Composition 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Type 1 × Continuous Glucose Monitoring × Clear all
NCT04942756 2021-07-22

GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Antea Foundation

Phase NA Unknown
118 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡